Objective: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker development; and (4) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures (SOPs).
The neurofibromatoses-neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN)-are genetically distinct neurocutaneous syndromes that share many features. All 3 conditions demonstrate wide variability in disease manifestations, and are characterized by progressive, lifelong, and potentially life-threatening complications. Standard treatment is limited to surgery for most tumor manifestations. Given the unmet need for nonsurgical therapies, there have been .20 clinical trials performed between 1993 and 2014 for NF1 and NF2 with varying measures of response. Few studies have documented evidence of clinical efficacy for investigational agents. 1 To date, no biomarker-driven trials have been performed in NF.
The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was created in 2011 to define and develop the most informative, reliable, and meaningful endpoints for clinical trials for NF. The REiNS group is composed of several working groups. 2 The biomarker working group, which includes neurologists, oncologists, geneticists, pathologists, dermatologists, pediatricians, and basic scientists, has the goals to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline initial recommendations for sample collection and biomarker development; and (4) harmonize sample collection and processing protocols where possible to allow for data comparison between studies by publishing standard operating procedures (SOPs).
This article summarizes the progress toward these goals. The biomarker group has concentrated on biomarkers in blood, urine, and tissue. Imaging biomarkers are discussed separately by the REiNS imaging working group. 3 METHODS The biomarker group first performed a literature search, and reviewed and summarized existing data on biomarkers in NF1, NF2, and SWN. The group then met during a series of meetings in collaboration with the Children's Tumor Foundation (1) to establish SOPs for sample collection of NF tissue specimens that facilitate data comparison between studies and (2) to develop a minimal clinical dataset that would accompany each sample. The working group anticipates that these recommendations will be updated periodically as new information on biomarkers becomes available. Detailed assay protocols will be available on the REiNS Web site (www.reinscollaboration.org).
RESULTS
Biomarkers are used for early detection of disease or in disease classification (diagnostic biomarkers), in predicting response or adverse events (predictive biomarkers), in defining optimal drug dose (metabolic/pharmacodynamic biomarkers), or in forecasting progression or recurrence (outcome biomarkers). 4 Previous natural history studies in NF1 and NF2 have clearly demonstrated a high degree of variability in disease phenotype and tumor behavior in these conditions. 5 This variability introduces complexity into the identification of valid biomarkers for NF and schwannomatosis. For example, a biomarker could potentially correlate with the presence of the genetic syndrome (e.g., NF1, NF2, or schwannomatosis), of a specific tumor type (e.g., gastrointestinal stromal tumor in NF1), with a nontumor phenotype of NF (e.g., pain severity in schwannomatosis), with cumulative disease burden (e.g., whole body tumor burden), with disease progression (e.g., growth of plexiform neurofibroma in NF1), or with malignant transformation (e.g., malignant peripheral nerve sheath tumor from plexiform neurofibroma). Given the overlap in many of these phenotypes, validating these biomarkers for individual disease manifestations will require careful phenotyping of patients.
Diagnostic biomarkers in NF. Historically, NF1, NF2, and schwannomatosis have been diagnosed using established clinical criteria. Advances in molecular techniques over the last 2 decades have led to the availability of genetic diagnosis for these conditions. 6, 7 The sensitivity of genetic analysis for diagnosis of NF depends on the founder status and the clinical phenotype (segmental vs generalized) but ranges from 30% for sporadic schwannomatosis to .95% for NF1. When a causative genetic alteration in the NF1, NF2, SMARCB1, or LZTR1 genes is identified, it can be used as diagnostic biomarker for related family members. In clinical practice, this information is used by reproductive endocrinologists for prenatal diagnosis or preimplantation genetic diagnosis and by genetic counselors for presymptomatic diagnosis of family members. However, additional diagnostic biomarkers will undoubtedly be useful to identify patients with specific disease features, such as plexiform neurofibromas or optic gliomas.
Outcome biomarkers in NF. Similarly, there is great variability in clinical outcomes for patients with NF. For example, while optic pathway glioma occurs in about 15% of individuals with NF1, only about 1/3 of these tumors are symptomatic, and less will progress and require active treatment. 8 Optic pathway gliomas will even spontaneously regress without treatment. This variability in outcome highlights the need to develop outcome biomarkers for NF disease manifestations. Outcome biomarkers provide evidence about the patient's disease outcome independent of any specific intervention. A validated outcome biomarker would be valuable to determine the long-term risk for dermal neurofibromas and malignant peripheral nerve sheath tumors in patients with NF1, for risk of complete deafness in patients with NF2, and for risk of severe chronic pain in patients with schwannomatosis.
Predictive biomarkers in NF. Over the last decade, there has been an explosion of clinical trials for NF-related tumors and conditions. The opportunity to study novel agents in NF opens the possibility of developing and incorporating biomarker studies into early clinical trials. To date, clinical trials run through the Neurofibromatosis Clinical Trials Consortium have included studies of pharmacodynamic biomarkers and predictive biomarkers. As drugs with activity against NF become available, these studies will provide valuable information about which patients are likely to require treatment in the future and which are likely to respond to therapy.
Existing data on biomarkers in NF1, NF2, and SWN.
During development, biomarkers pass through a series of stages, including early research and development (exploratory biomarker), demonstration and validation (probable biomarker), characterization and qualification (known biomarker), and surrogacy (biomarker can substitute for clinical endpoint). For the neurofibromatoses, all biomarkers published to date are considered exploratory; none has been validated to achieve probable biomarker status. Thus far, all published biomarker studies have been performed in the setting of NF1 (table 1) ; there are no published data on biomarkers in NF2 or schwannomatosis. These exploratory studies are all limited by a variety of technical issues such as limited statistical power, lack of an independent validation set, and lack of longitudinal data.
Diagnostic biomarkers in NF1.
• Melanoma inhibitory activity (MIA)-In a study of 42 patients with NF1 and 22 healthy controls, 9 MIA serum levels were significantly greater in patients with NF1 (15.2 ng/mL) than in controls (4.5 ng/mL), in patients with NF1 with plexiform neurofibromas (PNF) than in those without PNF, in patients with NF1 with high numbers of cutaneous or subcutaneous neurofibromas than in those without such tumors, and in patients with NF1 with greater internal tumor load than in those with low internal tumor load. In contrast, serum levels of MIA were not significantly different between patients with NF1 with and without malignant peripheral nerve sheath tumors (MPNST). MIA as a biomarker for NF1 was also investigated by another group. 10 This group added the analysis of the metabolite 5-S-cysteinyldopa (5-S-CD). They found concordant results with higher MIA levels in 25 patients with NF1 compared with 14 controls (13.1 vs 9.3 ng/mL) but did not find significantly different levels between patients with NF1 with or without PNF (15.1 vs 12.0 ng/mL, respectively).
In their study, serum 5-S-CD levels were significantly higher in patients with NF1 than in controls and did not correlate with age. Hence, MIA does not appear to be a robust biomarker for distinguishing unaffected controls from patients with NF1 or between patients with NF1 with or without MPNST. Further work is needed to explore the utility of 5-S-CD to distinguish between groups. • Adrenomedullin (ADM)-In a study of 32 patients with NF1 and 25 control patients, 11 serum ADM levels were significantly greater in patients with NF1 with MPNST (0.24 ng/mL, n 5 5) than in patients with NF1 with PNF (0.18 ng/mL, n 5 17); however, there was significant overlap in ADM levels between the cohorts. ADM levels were also significantly higher in patients with NF1 with or without MPNST (0.18 ng/mL, n 5 27) than in controls (0.07 ng/mL, n 5 25). No significant differences were noted between patients with NF1 with or without PNF. Although the data for ADM data are more promising than those for MIA, the current data do not indicate that ADM is a reliable biomarker in NF1 and further studies are warranted. • Fetal antigen 1-In a study of 13 adult patients with NF1 and 177 adult controls, 12 the median fetal antigen 1 levels were significantly higher in the serum of patients with NF1 (30.6 ng/mL) than in control patients (24.9 ng/mL), although there was considerable overlap between the groups. 12 • Soluble growth factor receptor Axl (sAXL)-In a study of 72 patients with NF1 and 46 healthy controls, serum levels of sAXL were significantly increased in patients with NF1 (23 ng/mL) compared with controls (16 ng/ mL). Patients with plexiform neurofibromas had significantly higher levels of sAXL (26 ng/mL, n 5 36) than patients with NF1 without plexiform neurofibromas (18 ng/mL, n 5 36) although there was still some overlap between groups. 13 • Systematic screen of multiple serum biomarkers 14 -The authors evaluated 104 patients with NF1 and 41 healthy controls and proposed 4 candidate biomarkers that were statistically significantly different in patients with NF1 vs unaffected individuals (interleukin-6, interferon-g, epidermal growth factor receptor, tumor necrosis factor-a) and 2 biomarker candidates that were statistically significantly different in patients with NF1 with and without MPNST (insulin-like growth factor binding protein 1 and RANTES). • Danielsen et al. 15 analyzed the promoter methylation of RASSF1A in primary tumor. The authors reported significantly different survival data for 32 patients with methylated or unmethylated RASSF1A at 5 years. • MiRNA studies in NF1 and non-NF1 MPNSTs have been performed using cell lines and tissues. This study identified the downregulation of miR-204 as a novel diagnostic biomarker and potential therapeutic target for patients with NF1 with MPNSTs. 16 All the above-mentioned studies were aimed at identifying diagnostic biomarkers.
Predictive and pharmacodynamic biomarkers.
• Candidate gene alterations in tumor specimens-Using high-resolution array-based comparative genomic hybridization in 38 MPNSTs (23 with NF1 and 15 without NF1), the authors identified candidate gene alterations that were then validated at the DNA, RNA, and protein levels. 17 Candidate genes in regions of copy number gain and associated (predicted) with poor survival included SOX5, NOL1, MLF2, FOXM1, FKBP1, CDK4, TSPAN31, ERBB2, MYC, and TP53. In multivariate analysis, FOXM1 protein expression and CDK4 copy number gain were the most significant independent genomic biomarkers for poor survival in patients with MPNSTs. • Aurora kinase A, which is important in mitotic spindle assembly and nonmitotic related cell differentiation, is a potential therapeutic target in MPNSTs. Recent studies in primary MPNSTs have demonstrated that pharmacologic aurora kinase inhibition results in MPNST cells exiting the cell cycle with cessation of growth. 18 The copy number and expression of the gene product HMMR was found to be a functional marker of responsiveness to aurora kinase inhibition. A variety of less well-defined and reproducible prognosticators are summarized in a review by Farid et al. 19 • Recently, gene expression analysis of 30 MPNSTs and subsequent immunohistochemical staining of 64 MPNSTs revealed a composite set of survivin (BIRC5), thymidine kinase 1 (TK1), and topoisomerase 2-a (TOP2A) immunohistochemical staining, which stratifies MPNST into high and low risk 20 independent of age, sex, tumor size, grade, NF1 status, and surgical remission. • Blakeley et al. 21 have detected lower blood circulating levels of hepatocyte growth factor in patients with NF2 who responded to bevacizumab. This is the first evidence that a blood biomarker could be used predictively to stratify patients with NF2 (n 5 13) with the highest likelihood of treatment benefit.
RECOMMENDATIONS FOR SAMPLE COLLECTION
AND METHODOLOGY The REiNS biomarker group discussed potential barriers to biomarker research for NF. These barriers include the low prevalence of NF1, NF2, and schwannomatosis, which makes coordinated studies technically difficult and expensive; the extreme variability of these conditions requires expert clinical researchers to accurately phenotype patients. Based on this discussion, the group endorsed the following goals to advance the study of biomarkers within the NF community: on encouraging preliminary data as biomarkers of cancer. 22 5. Using candidate approach, focus on the clinically relevant questions, i.e., total tumor load, presence of plexiform neurofibroma, evidence of malignant transformation, and taking into account the statistical significance in published studies. We recommend validating the following biomarker candidates in patients with NF1: BIRC5/TK1/TOP2A immunohistochemistry, ADM, interferon-g, IGFBP-1, and sAXL. 6. Complement candidate biomarker approach with systematic unbiased approach. Encourage well-powered studies using systematic unbiased approaches, including genomics (DNA, RNA, miRNA next-generation sequencing), metabolomics, and proteomics; that is, further screening with metabolomics, proteomics, expression arrays, and miRNA.
